Trial Profile

An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Efinopegdutide (MK-6024) in Participants With Moderate and Severe Hepatic Impairment

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Efinopegdutide (Primary)
Indications Non-alcoholic steatohepatitis
Focus Pharmacokinetics
Sponsors Merck Sharp & Dohme

Most Recent Events

16 Dec 2024 Status changed from active, no longer recruiting to completed.
02 Dec 2024 Planned End Date changed from 6 Jan 2025 to 6 Dec 2024.
02 Dec 2024 Planned primary completion date changed from 6 Jan 2025 to 6 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com